Aldeyra Therapeutics Inc President and CEO Todd Brady Sells Company Shares
Todd Brady, President and CEO of Aldeyra Therapeutics Inc (NASDAQ:ALDX), has sold 183,238 shares of the company on March 12, 2024, according to a recent SEC Filing. This transaction has been part of the insider's trading activities over the past year, during which the insider has sold a total of 183,238 shares and has not purchased any shares.
Aldeyra Therapeutics Inc is a biotechnology company focused on the development of products for inflammation, inborn errors of metabolism, and other diseases that are thought to be related to endogenously generated toxic and pro-inflammatory chemical species known as aldehydes.
The insider transaction history for Aldeyra Therapeutics Inc shows a pattern of insider sales over the past year, with 0 insider buys and 4 insider sells recorded during the same timeframe.
On the date of the insider's most recent transaction, shares of Aldeyra Therapeutics Inc were trading at $3.17 each, giving the company a market capitalization of approximately $176.98 million.
The insider's recent sale represents a significant change in ownership and may be of interest to investors monitoring insider behaviors and patterns as part of their investment research.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
This article first appeared on GuruFocus.
